Clinical Trial Update: A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies [Phase 1, Phase 2]

View source ↗

Summary

The completed Phase 1/2 trial evaluated the safety and preliminary efficacy of a MUC1 peptide vaccine in combination with hGM-CSF for patients with MUC1-positiv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• MUC1 peptide vaccine (MUC1 peptide vaccine)
• hGM-CSF (human granulocyte-macrophage colony-stimulating factor)

Snippet

Sponsor: Vaxil Therapeutics Ltd. | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED